|
累計回購金額75.97億港元。合計回購9115.12萬股，該股當日收盤價52.300港元 ，4月8日以每股52.050港元至53.000港元的價格回購10.00萬股， 自1月26日以來公司已連續47日進行回購， 今年以 |
光算蜘蛛池光算谷歌seo代运营光算谷歌seo光算爬虫池光算谷歌seo光算蜘蛛池光算谷歌seo代运营光算谷歌推广光算谷歌推广光算谷歌营销光算谷歌seo公司https://synapse.patsnap.com/drug/6267e7c2013b4ba3b7325b39279463d6https://synapse.patsnap.com/drug/2b29690b7da44c7999597f6f38c8ed19https://synapse.patsnap.com/article/what-are-egr1-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-proxyphylhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-naproxen-sodiumhttps://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-teplizumabhttps://synapse.patsnap.com/drug/4daf10e8248646af80e5b347d318b7d6https://synapse.patsnap.com/drug/005934e4a0f248c693727ad610d61abehttps://synapse.patsnap.com/drug/3f52e6757cc7414a8f53454629e88c68https://synapse.patsnap.com/drug/8c21f13c3e8749ab84a415d1a9d5b5f8https://synapse.patsnap.com/drug/00683c01a4824913a594f8b46fd63b3chttps://synapse.patsnap.com/drug/3c1f820eae554782b64866ffc286a667https://synapse.patsnap.com/article/what-are-tnfrsf11b-stimulants-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-erythromycin-ethylsuccinate-used-forhttps://synapse.patsnap.com/drug/198dbc0abf923374a7f2790ddb8a6ccdhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-sodium-gualenate-hydratehttps://synapse.patsnap.com/article/yunovia-gains-mfds-ind-approval-for-phase-1-mad-study-on-glp-1-agonisthttps://synapse.patsnap.com/drug/e3fd1ee7b5b441f39dedad458856ffe2https://synapse.patsnap.com/article/prokarium-expands-ip-portfolio-with-two-new-us-patentshttps://synapse.patsnap.com/drug/80b77d2a93ce4f7a980c6ed64580c06ahttps://synapse.patsnap.com/blog/the-synapse-users-toolkit-tips-for-searching-naltrexonehttps://synapse.patsnap.com/drug/2f33eea3c89444aea06b6ea16ad736eahttps://synapse.patsnap.com/article/cellenkos-ck0801-receives-fda-orphan-drug-status-for-aplastic-anemia-treatmenthttps://synapse.patsnap.com/drug/730ab34a02aa415c9cfd2ae27c83ce3dhttps://synapse.patsnap.com/article/cetuximab-beta-approved-in-china-by-nmpa-announces-simcere-zaiminghttps://synapse.patsnap.com/drug/7f2aef54a8b54328b0c4aee2840af467https://synapse.patsnap.com/drug/dc432fc208ca476a97840e9900f70482https://synapse.patsnap.com/drug/e483d5d625e4cc96d647aa4d2b26755fhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-epalrestathttps://synapse.patsnap.com/blog/what-does-semaglutide-do